PET tracer · neuroendocrine tumors
Ga-68 dotatate is a diagnostic radiotracer: a somatostatin-like peptide (octreotate) that carries the positron-emitting isotope gallium-68 through an attached DOTA chelator. Injected before a PET scan, it highlights neuroendocrine tumors that carry somatostatin receptors. It is prepared on site from the Netspot kit and is an imaging agent, not a treatment.
Many neuroendocrine tumors, including those arising in the gut, pancreas and lungs, carry far more somatostatin receptors than surrounding tissue, especially subtype 2 (SSTR2). Dotatate is a cyclic eight-amino-acid analog of somatostatin with a DOTA cage attached, and the cage holds gallium-68. After injection the peptide binds SSTR2-rich cells, and gallium-68 emits positrons that a PET scanner detects, producing a map of receptor-positive tissue. The gallium-68 comes from a generator and is attached to the peptide with the kit shortly before the scan. Uptake is not limited to these tumors: the uncinate process of the pancreas, displaced spleen tissue (splenosis), inflammation and some other tumor types can also take it up, so images need expert reading3.
The evidence is human imaging data. In a prospective study of 97 patients with known or suspected lung or gastroenteropancreatic neuroendocrine tumors, 78 had both Ga-68 dotatate PET/CT and the older indium-111 pentetreotide scan; adding Ga-68 dotatate results changed management in 36 percent, and only mild, transient events such as one case of fast heart rate were recorded1.
In a prospective study of 131 patients with gastroenteropancreatic neuroendocrine tumors, Ga-68 dotatate PET/CT detected 95 percent of lesions, compared with 45 percent for CT or MRI and 31 percent for indium-111 SPECT/CT, and found a previously unknown primary tumor in 4 of 14 such patients2.
In the largest of the three studies summarized on the FDA label, Ga-68 dotatate agreed with CT or MRI in 74 of 78 patients and was positive in 13 whose indium scan was negative; the other two studies recorded some false-negative and false-positive reads3. These studies measured detection and management changes, not survival.
The FDA approved Netspot in 2016 as a kit for preparing Ga-68 dotatate, for PET localization of somatostatin receptor-positive neuroendocrine tumors in adults and children3.
The label reports that the three single-center studies and literature survey behind its approval identified no serious adverse reactions3. After approval, nausea, vomiting, injection-site pain or burning, and allergic reactions (mostly rash and itching, less often angioedema or anaphylaxis-like reactions) have been reported. The scan adds to lifetime radiation exposure, which is associated with increased cancer risk, and the label advises limiting close contact with infants and pregnant women for the first 12 hours. Uptake in non-tumor tissue can lead to misreading3.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.
Brand names on this page belong to their owners and are used only to identify a product. goodtides is not affiliated with those companies.